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Abstract 
Safe, long-term gene expression is a primary criteria for effective gene therapy in the brain, so studies were initiated to evaluate 
adeno-associated virus (AAV) vector transfer of a reporter gene into specific sites of the rat brain. In the 4 day old rat, site infusions of 
AAV-CMV-lacZ ( l  /./,1; 5 )< 104 particles) produced neuronal /3-galactosidase g ne expression 3 weeks later in the hippocampus and 
inferior colliculus, but not in the cerebral cortex. Seven days after infusion of AAV-CMV-lacZ viral vectors (1 /xl) in the adult rat, 
/3-galactosidase gene expression was found in the olfactory tubercle, caudate, hippocampus, piriform cortex and inferior colliculus, 
primarily in multipolar neurons close to the infusion site. Three months after vector microinfusion, similar levels of gene expression 
remained in the olfactory tubercle and the inferior colliculus, with some reduction found in the caudate, but substantial reductions in 
/3-galactosidase gene expression occurred in the hippocampus and piriform cortex. In no case were obvious signs of toxicity noted. 
Therefore, AAV vectors can transfer foreign genes into the adult and neonatal CNS, but the pattern and longevity of gene expression 
depends upon the area of brain being studied. 
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1. Introduction 
There are a number of degenerative diseases and ge- 
netic disorders where the resulting CNS pathology might 
be ameliorated, or even prevented, following the introduc- 
tion of specific genes into the CNS. In cases where 
treatment would be aimed towards a degenerative disease, 
such as Parkinsonism, the therapeutic gene(s) must be 
transduced within non-mitotic ells of the adult brain. For 
inborn genetic diseases, the gene(s) must be introduced 
into the developing CNS. In either situation, long term 
gene transfer and expression must be accompanied by a 
low neurotoxic liability. 
Significant advances have been made towards these 
goals by a number of investigators who have demonstrated 
successful gene transfer into the adult CNS. Palella et al. 
[17] showed that a herpes simplex virus type-1 (HSV-1) 
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vector readily transferred genetic material into CNS neu- 
rons in vivo. Although the HSV-1 vectors efficiently trans- 
fer genetic material, they are usually accompanied by 
substantial neurotoxicity that to date has not been over- 
come [16]. Adenovirus vectors also have been used to 
transfer genetic material into the CNS with few signs of 
neurotoxicity [1,8]. However, these viral vectors are episo- 
mal, thus transient, and increased titers of these vectors 
can cause neural damage [1]. A third viral vector system 
utilizes the adeno-associated virus (AAV), a widespread 
parvovirus that has no known associated pathology in man 
[2]. Using unique properties of this virus, an AAV vector 
composed of only cis-acting terminal repeats can transfer 
genetic material into the non-mitotic cells, but has no 
means of wild-type virus recombination [19]. Recently, 
Kaplitt et al. [7] showed that such an AAV vector could 
transfer an E. coli /3-galactosidase (lacZ) gene, or a 
tyrosine hydroxylase gene, and produce expression of the 
gene product in the CNS with no obvious signs of neuro- 
toxicity. More importantly, for up to 3 months, expression 
of tyrosine hydroxylase within the caudate nucleus par- 
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tially ameliorated the motor deficits caused by a prior, 
unilateral dopamine lesion. Even though the level of cor- 
rection remained the same from 1 to 3 months, the level of 
tyrosine hydroxylase xpression diminished somewhat over 
time. 
These studies in the caudate nucleus established the 
ability of AAV-mediated gene therapy to ameliorate a 
degenerative CNS process, but targets of CNS gene ther- 
apy include a variety of brain sites, as well as different 
stages of development. Given the heterogeneity of the 
CNS, gene expression and longevity, as well as neurotoxi- 
city, might vary across different brain areas. Therefore, the 
following studies characterized age-, time- and site-depen- 
dent gene expression patterns using the AAV vector deliv- 
ery system. 
2. Materials and methods 
2.1. Animals 
All of the animals were pathogen-free, male or female 
Sprague-Dawley rats obtained from Charles Rivers Associ- 
ates (Raleigh, NC), or bred within the animal colony. The 
animals were maintained in a 12:12 h l ight/dark cycle and 
had free access to water and food. All care and procedures 
were in accordance with the Guide for the Care and Use of 
Laboratory Animals (DHHS Publication No. (NIH)85-23), 
and all procedures received prior approval by the IACUC 
at the university. 
2.2. AA V Vector preparation 
The AAV vector used in these studies was constructed 
by inserting the E. coli /3-galactosidase g ne (lacZ) into 
an AAV vector plasmid. Briefly, plasmid d13-94 neo [14] 
was partially digested with restriction enzyme PstI. The 
2.2 kb fragment containing AAV terminal repeats and the 
neo gene was cloned into the PstI site of plasmid pGEM- 
3Z (Promega), generating plasmid pdx-31. A plasmid con- 
taining the lacZ gene, driven by a CMV early promoter 
(pCMV-lacZ, Clontech), was digested with Sall and filled 
in by Klenow fragment. The plasmid was subsequently 
digested with PstI. The 4.0 kb CMV-lacZ fragment was 
gel purified and ligated with the 3.4 kb NsiI-SnaBI frag- 
ment from pdx-31, generating AAV vector plasmid 
pdx31-lacZ. 
AAV-lacZ viral particles were produced by cotransfect- 
ing the vector plasmid pdx31-lacZ with the helper plasmid 
AAV/AD into adenovirus-infected 293 cells [19]. Briefly, 
25 /xg of plasmid DNA (6 /xg vector plus 19 /xg helper) 
was transfected by calcium phosphate precipitation into 
293 cells at 80% confluency in DMEM plus 10% FBS. 
The medium was replaced after 8 to 12 h transfection with 
fresh DMEM plus 2% FBS. Adenovirus 5 was added to 
the cells at 1 m.o.i. (multiplicity of infection). After two 
and a half days, the cells were harvested and freeze/thawed 
three times. Cell debris was removed by low-speed centrif- 
ugation. The supernatant containing AAV-lacZ was gently 
extracted 2 to 3 times with equal volume of chloroform, 
and the residual chloroform was evaporated with nitrogen. 
To the supernatant, one-third volume of saturated ammo- 
nium sulfate solution was added to make 25% saturation. 
The sample was placed on ice for 10 min and centrifuged 
at 15,000 × g for 10 min. The supernatant was recovered 
and saturated ammonium sulfate solution was added to 
make 50% saturation. The sample was placed on ice for 10 
min and centrifuged at 15,000 × g for 10 rain. The pellet 
was redissolved in cesium chloride-PBS solution (density 
1.38 g /ml )  and centrifuged at 40,000 rpm for 48 h. This 
step separates the AAV from the adenovirus. The AAV 
band was collected, dialyzed against DMEM and heated at 
56°C for 15 to 30 min. Thus, any adenovirus will be 
inactivated. The AAV-lacZ virus titers were determined by 
infecting 293 cells at various dilutions. The cells were 
fixed and stained with X-gal, according to the methods of 
Hatton and Lin [5]. 
2.3. AA V Microinjection 
The microinfusion of AAV-IacZ into 4-day-old neona- 
tal rats utilized a modification of a previous technique [13]. 
In these studies, the day of birth was considered post-natal 
day 0, and by post-natal day 2 the litters were culled to 10 
pups. Then, on post-natal day 4, the rat pups were anes- 
thetized with ether and a 2-3  mm incision was made in the 
skin over the skull. Using the suture lines, rostral-caudal 
and medial lateral coordinates were determined, and the 
intersection was marked on the skull. A small hole was 
drilled in the skull with a 26-gauge needle, and a 33-gauge 
injector was lowered to the appropriate depth. After infu- 
sion of the AAV-lacZ vector (1/xl over 9 min; 5 x 104 
particles//xl), the injector was left in place for 1 min 
post-infusion. The incision was sutured, and the rat pups 
were placed in a plexiglass cage over a heating pad. 
Within 2 h, the pups were returned to the dam. For the 
adult rats (Sprague Dawley, 45-60 days of age) microin- 
jections of AAV-IacZ vectors into specific brain sites was 
accomplished using a previously described procedure [10]. 
First, the rats were anesthetized with pentobarbital (50 
mg/kg)  and placed into a stereotaxic frame. The skull was 
exposed and a hole drilled over the site to be microinjected 
using coordinates from the atlas of Paxinos and Watson 
[18]. A 33-gauge stainless teel tube was lowered into the 
site and 1-2 /xl of AAV-lacZ vectors (5 X 104 
particles//xl) were infused at a rate of 1 /xl per 9 rain. The 
injector was left in place for 1 rain post-infusion to allow 
diffusion from the injection site. The hole was filled with 
bone wax, and the incision site sutured. For lateral ventric- 
ular administration, 5 or 10 #1 of the AAV-lacZ vector 
solution was infused into the lateral ventricle at a rate of 5 
/xl per 9 rain. 
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2.4. fl-Galactosidase histochemistry and immunohisto- 
chemistry 
On post-natal day 25, or for adults, 7 days or 3 months 
after AAV- lacZ vector infusion, animals were anesthetized 
with 100 mg/kg  pentobarbital, i.p. and perfused transcar- 
dially with ice-cold 100 mM sodium phosphate buffered 
saline (PBS) (pH 7.4), followed by 4% paraformaldehyde 
in 100 mM phosphate buffer (pH 7.4). After overnight 
fixation in the paraformaldehyde-phosphate buffer, vi- 
bratome sections (40 /xm thick) were taken and rinsed in 
PBS. For X-gal histochemistry, sections were mounted on 
slides and processed according to the methods of Hatton 
and Lin [5]. For the immunohistochemistry, issue sections 
were incubated in 10% normal horse serum and 0.2% 
Triton X-100 in PBS for 30 min. Next, sections were 
incubated with a monoclonal antibody to /3-galactosidase 
(1:2000 dilution; Chemicon) in 3% normal rabbit serum, 
0.2% Triton X-100 and PBS for 48 to 72 h at 4°C. In some 
instances, adjacent sections were incubated with a mono- 
clonal antibody to glial fibrillary acid protein (GFAP) 
(1:2000 dilution, Boehringer Mannheim). Tissue sections 
were then rinsed three times in PBS and processed through 
secondary biotinylated horse anti-mouse antibody and 
avidin-biotin complex using a Vectastain Mouse Elite ABC 
Kit (Vector Laboratories, Burlingame, CA). Visualization 
of FLI was achieved by nickel/cobalt enhancement of 
3,3'-diaminobenzidine tetrahydrochloride [6]. 
3. Results 
3.1. AAV-IacZ gene transfer and expression in the hip- 
pocampus 
Fig. 1 illustrates the structure of the AAV- lacZ vector 
used in the present experiments. Briefly, it can be seen that 
96 percent of the AAV genome containing the replication 
and encapsidation genes has been removed and replaced 
with a lacZ-cytomegalovirus (CMV) promoter cassette. 
Thus, this viral vector does not have the ability to recom- 
bine with wild type virus. When 2 /zl of this AAV- lacZ 
vector (5 X 10 4 particles/~l) was infused into the hip- 
pocampus, 7 days later histochemical determination of 
/3-galactosidase activity revealed reaction product localized 
primarily to large multipolar neurons in the hilus and 
pyramidal cell layers (see Fig. 2). Some reaction product 
also was present in the neuropil, but reaction product was 
noticeably absent in the dentate granule cells. Fig. 2 also 
illustrates the restricted spread of the AAV vector trans- 
duction, and the lack of obvious neurotoxicity. Labeled 
cells were found 400-500 /.~m distal to the infusion site, in 
a rostral-caudal direction and up to 1.5 mm in a medial- 
lateral direction. However, neural damage was restricted to 
the tip of the injector and no more extensive than would be 
expected for a 2 /.1,1 infusion. There were no obvious signs 
SV splicing 
Fig. 1. Schematic diagram of the AAV-IacZ vector. ITR stands for the 
inverted terminal repeat of the AAV vector. CMV stands for the early 
promoter from human cytomegalovirus, lacZ is the fl-galactosidase gene 
from E. coli. SV splicing and SV polyA represent the SV40 splicing site 
and polyadenylation site, respectively. 
of gliosis or cell damage within areas containing gene 
expression. 
3.2. AA V-lacZ gene transfer and expression in the neonate 
When 1 /zl of the AAV- lacZ vector was microinjected 
into different brain sites of the 4-day-old rat, a variable 
pattern of expression was found at 25 days of age. In the 
hippocampus,/3-galactosidase immunoreactivity was found 
in the neuropil and large multipolar cells in close proxim- 
ity to the infusion site (see Fig. 3). In contrast, no neurons 
exhibited /3-galactosidase immunoreactivity after infusion 
into the piriform cortex of 4 neonates. When AAV-lacZ 
was infused into the inferior colliculus, many multipolar 
neurons exhibited /3-galactosidase immunoreactivity (see 
Fig. 3), as well a few glial cells. In one animal, the injector 
coursed through the inferior colliculus into the adjacent 
central gray. As seen in Fig. 3, the remnants of a labeled 
dendrite comprises the extent of /3-galactosidase immuno- 
reactivity along the injector path in the central gray, while 
substantial fl-galactosidase expression begins at the infe- 
rior collicular border and continues along the injector tract 
in the inferior colliculus. In all of the infusions, there were 
no obvious signs of damage beyond damage xpected from 
the microinjection. 
3.3. AA V-lacZ gene transfer and expression in different 
brain sites of  the adult at 1 week and 3 months 
When 1 /xl volumes of AAV- lacZ vectors were in- 
fused, differential site and temporal patterns of gene ex- 
pression were found. In the hippocampus, large multipolar 
neurons were labeled 1 week after AAV- lacZ infusion, but 
3 months after the same infusion, the number of/3-galacto- 
sidase positive cells was substantially reduced (see Fig. 4). 
Similarly, Fig. 4 shows that 1 week after the vector 
infusion into the piriform cortex, numerous large pyrami- 
dal cells contained /3-galactosidase immunoreactivity, but 
3 months later, both the number and extent of /3-galacto- 
sidase positive cells was dramatically reduced. When 
AAV- lacZ vectors were infused into the caudate nucleus, 
some /3-galactosidase positive cells were found 1 week 
later (see Fig. 4), but the number proved less than in the 
hippocampus or piriform cortex. Three months later, the 
number of fl-galactosidase positive cells had decreased, 
but given the low number of positive cells at 1 week, this 
decrease did not appear as dramatic as that found in the 
hippocampus and piriform cortex. 
t-
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Fig. 3. The expression of fl-galactosidase 3 weeks after the infusion of 1 /xl of AAV-lacZ vectors (5 X 10 4 panicles//xl) into the hippocampus (A) or 
inferior colliculus (B) of the 4-day-old rat. In both the hippocampus and the inferior colliculus, multipolar neurons comprise the majority of the cells 
labeled for/3-galactosidase immunoreactivity. In panel C, the injector coursed through the inferior colliculus and into the central gray. A dendritic remnant 
remains labeled near the tip of the injector ( * ), but little expression occurs until the border of the inferior colliculus, where substantial f -galactosidase 
immunoreactivity is found. The large labeled cells demarcate the border between these adjacent brain structures. DG, dentate granule cell layer of the 
hippocampus; ic, inferior colliculus; cg, central gray. Bar = 50 /zm. 
In direct contrast, two brain areas exhibited similar 
amounts of gene transfer and expression both at 1 week 
and 3 months. As seen in Fig. 5, AAV- lacZ  vector infu- 
sion into the olfactory tubercle resulted in a moderate 
number of /3-galactos idase posit ive multipolar neurons at 1 
week. Similar numbers of labeled, multipolar neurons were 
found 3 months after AAV- lacZ  vector infusion. When 
AAV- lacZ  vectors were infused into the inferior coll icu- 
lus, a substantial number of  /3-galactosidase posit ive neu- 
rons were present both at 1 week and 3 months (see Fig. 
5). Even though the inferior col l iculus exhibits a high level 
of long-term transduction, GFAP  immunohistochemistry in 
adjacent sections did not reveal obvious signs of glial 
reactivity (see Fig. 6). 
In all of these brain areas, /3-galactosidase immuno- 
reactivity was restricted to the immediate vicinity of  the 
infusion, occurring primari ly in neurons. However,  there 
were a few instances where f l-galactosidase immuno- 
reactivity was found in a clearly identif ied astrocyte. Also, 
when 5 or 10 /zl of  the AAV- lacZ  vectors were infused 
into the lateral ventricle, 7 days later f l-galactosidase was 
found in ependymal cells close to the site of  infusion, but 
not in adjacent brain structures. 
4. Discussion 
When AAV- lacZ-CMV promoter vectors are microin- 
fused into the brain, 15 to 40 /~m diameter neurons 
represent the major cell type where transfer and expression 
of  f l-galactosidase occurs. However,  different levels of 
gene transfer and expression were found both across and 
within different brain regions. After a 1 /xl infusion, the 
caudate nucleus exhibited the fewest number of labeled 
cells, never more than 10 cells in a given section. A 
greater number of cells were found in the olfactory tuber- 
Fig. 2. The expression of /3-galactosidase activity in adult hippocampus 7 days after a 2 /xl infusion of AAV-lacZ vectors (5 X 10 4 particles//xl) using 
X-gal histochemistry in cresyl violet-stained 40-#m thick sections. In panel A the large arrow demarcates the tip of the injector, while the blue reaction 
product illustrates the extent of the fl-galactosidase expression. Upon enlargement (panel C), notice that large multipolar neurons in the hilus of the dentate 
gyrus, dendrites and some neuropil exhibit /3-galactosidase activity. However, no labeling is present in the dentate granule cell layer, outlined by the small 
arrows. Panel B represents a section 400 ~m distal to the injection site. Again most labeling occurs in multipolar neurons, dendrites and neuropil, but no 
labeling is found in the dentate granule cells. In the enlargement (D), both large multipolar neurons, as well as the outline of the dentate granule cell layer 
can be seen. Bar - 50 /xm. 
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cle, between 10 and 20 cells in a given section. The 
greatest number of labeled cells were generally found in 
the piriform cortex, hippocampus and inferior colliculus. 
Usually, sections from these areas exhibited more than 20 
labeled cells per section, while in the case of the inferior 
colliculus, some sections had greater than 50 /3-galacto- 
sidase positive cells in a given section (see Fig. 5). How- 
ever, within given brain regions, not all neurons exhibited 
/3-galactosidase expression. For example, while many mul- 
tipolar neurons were /3-galactosidase positive in the hip- 
pocampus, j3-galactosidase activity was noticeably absent 
in the dentate granule neurons (see Fig. 2). Also, there 
were instances where other cells types exhibited gene 
transfer and expression. After ventricular administration, 
' I  
j 
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Fig. 5. The expression of /3-galactosidase in adult inferior colliculus and olfactory tubercle 7 days and 3 months after a 1 /.1.1 infusion of AAV-IacZ 
(5 X 10 4 particles/#l). For the inferior colliculus, numerous neurons exhibited /3-galactosidase immunoreactivity both 7 days (A) and 3 months (B) after 
AAV vector infusion. These findings were consistent for the 7-day (n = 5) and 3-month (n = 3) groups. Similarly, in the olfactory tubercle, a moderate 
number of neurons exhibited fl-galactosidase immunoreactivity both 7 days (C) and 3 months (D) after AAV vector infusion. Likewise, these findings 
were consistent for the 7-day (n = 4) and 3-month (n = 3) groups. Bar = 50 #m. 
ependymal  cel ls  l in ing the vent r i c les  were  pos i t ive  for 
/3-galactos idase,  and occas iona l ly ,  gl ia d id exh ib i t  expres -  
s ion o f  f l -ga lactos idase .  In the case o f  astrocytes ,  the 
re lat ive lack o f  labe l ing  does  not  appear  to be a prob lem 
wi th  detect ion  sens i t iv i ty ,  because  in one case,  a labe led  
ast rocyte  was  c lear ly  ident i f ied  in the caudate  nuc leus .  
A l though express ion  appears  to favor  large mul t ipo lar  
neurons ,  this observat ion  does  not  mean that the AAV 
vectors  are on ly  taken up into mul t ipo la r  neurons  or  that 
gene  t ransfer  is more  ef f ic ient  in neurons .  It on ly  means  
that w i th  the AAV vector  under  contro l  o f  the CMV 
promoter ,  express ion  o f  the gene  product  occurs  prefer -  
ent ia l ly  in mul t ipo lar  neurons.  G iven  a other  vectors  or 
p romoters ,  the pattern o f  gene  t ransfer  cou ld  be quite 
d i f ferent .  For  example ,  Le Gal La Sal le et al. [8] found 
/3-galactos idase express ion  in the dentate  granule  cel ls,  but  
not  the hi lus or pyramida l  cel l  layer,  after h ippocampal  
in fus ion  o f  an adenov i rus  vector  dr iven by a Rous  sarcoma 
Fig. 4. The expression of /3-galactosidase in adult hippocampus, piriform cortex and caudate nucleus 7 days and 3 months after a 1 /xl infusion of 
AAV-lacZ (5 x 10 4 particles//zl). In the hippocampus, a number of large multipolar neurons are labeled in the pyramidal cell region of CAI(A; 
= injector tip), but 3 months after an infusion into the same area (B; * = injector tip), only one neuron exhibits /3-galactosidase immunoreactivity. For 
the 7-day survival group, there were at least 10 labeled cells per section (n = 5), while the 3-month survival group never exhibited more than 5 labeled 
cells in a section (n = 3). Panels C and D show the 7-day and 3-month post-infusion results respectively for the piriform cortex. At 7 days, substantial 
labeling was found primarily in pyramidal cells and their dendrites (C), but by 3 months after the AAV vector infusion (D), only a few cells exhibited any 
/3-galactosidase immunoreactivity near the tip of the injector ( * ). Again, the 7-day survival group exhibited greater than 20 cells per section (n = 4), while 
the 30-day survival never exhibited greater than 10 cells per section or any dendritic labeling (n = 3). In the caudate nucleus, some multipolar neurons are 
labeled in close proximity to the injector tract (E), but by 3 months fewer neurons were positive for /3-galactosidase immunoreactivity around the injector 
tract (F). In the 7-day group (n = 5), there were never more than 10 positive cells in a given section, while in the 3-month group, there were never more 
than 5 positive cells in a given section (n = 3). Bar = 50 p~m 
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Fig. 6. GFAP immunoreactivity in sections from the inferior colliculus 3 
months aflcr thc injection of 1 /zl AAV-lacZ (5 × 104 particles/#1). It 
can be seen that he pattern of astrocyte GFAP immunoreactivity in the 
section contralateral to the AAV vector infusion (A) does not appreciably 
differ from the GFAP immunoreactivity on the infused side (B). The 
adjacent section to B exhibited /3-galactosidase immunoreactivity similar 
to that found in Fig. 5, panel B. Bar = 50 /xm. 
virus long terminal repeat promoter. Further investigations 
will be necessary to delineate any cell specific differences 
in the AAV-vector uptake, gene transfer or promoter driven 
gene expression. 
These studies also showed that AAV vectors can effec- 
tively transfer foreign genes into the neonatal brain, but the 
expression of /3-galactosidase proved to be site specific. 
Substantial /3-galactosidase expression was found in the 
hippocampus and inferior colliculus, but not in the piri- 
form cortex. One explanation for this difference could be 
the stage of brain development. For example, the lack of 
neural labeling in the cortex might be attributed to the fact 
that in 4-day-old rats, pyramidal cells are still migrating 
along the radial glia towards their final destination [15]. 
Alternatively, there could be site-specific differences in 
promoter regulation. Clearly, dramatic gene expression 
differences were found between two adjacent structures, 
the central gray and the inferior colliculus. Thus, in the 
neonate, the pattern of gene expression likely depends 
upon both differences in promoter egulation, as well as 
the stage of development. Again, future studies will be 
necessary to define the actual contribution of these pro- 
cesses to gene transfer and expression in the neonatal 
brain. 
In the adult rat, AAV vectors are capable of long-term 
transfer and expression of a foreign gene without overt 
signs of neurotoxicity, but the longevity of expression is 
brain site specific. In the piriform cortex and the hip- 
pocampus, the number of cells expressing /3-galactosidase 
at 3 months was dramatically lower than the number found 
7 days post-infusion. In the caudate nucleus, the amount of 
expression at 7 days was not as high as in the cortex or 
hippocampus, but there still appeared to be some decline in 
the number of /3-galactosidase-positive cells at 3 months. 
However, it must be noted that even with such a decline in 
expression, Kaplitt et al. [7] found that AAV transfer and 
expression of tyrosine hydroxylase in the caudate was 
sufficient o partially reverse a lesion-induced motor deficit. 
Thus, for some disorders, partial ong-term expression may 
be therapeutically sufficient. In marked contrast, both the 
olfactory tubercle and the inferior colliculus exhibited the 
same relative amount of /3-galactosidase expression at 7 
days and 3 months. Furthermore, in the inferior colliculus, 
there were no obvious signs of reactive astrocytes, so 
AAV-mediated long term gene expression did not produce 
obvious signs of neurotoxicity. 
These site-specific differences in long-term gene ex- 
pression could be attributed to variable expulsion of the 
vector or differential regulation of the CMV promoter. 
Given the difficulties with finding promoters capable of 
long term expression [4], and recent findings by Bloom et 
al. [3], it seems likely that inactivation of the promoter 
underlies our observed ecline in gene product expression. 
For example, Bloom et al. [3] recently demonstrated long- 
term expression of /3-galactosidase in the hippocampus 
using an HSV vector and a latency associated transcript 
promoter from murine moloney leukemia virus. However, 
the 6-month level of gene expression was substantially ess 
than the levels of expression at 2 weeks, even though the 
amount of viral DNA did not change over this time period. 
In the present studies, differential suppression of the CMV 
promoter would explain why some brain areas exhibited a
long term decline in /3-galactosidase expression, while 
other brain areas showed no decline in /3-galactosidase 
expression. Clearly, additional studies will be necessary to 
confirm this supposition. 
In conclusion, these studies show that an AAV- IacZ  
vector can transfer genetic material into neurons of the 
CNS and in some brain regions, expression of the gene 
product remains for at least 3 months without obvious 
signs of neurotoxicity. In other brain regions, the expres- 
sion of the gene product decays over time. Thus, findings 
on viral vector gene transfer in one brain area may not 
generalize to other brain areas. Just as important, with the 
AAV vector and the CMV promoter, both neonatal and 
long-term adult expression of /3-galactosidase was found 
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in the inferior coll iculus. Since neonatal and adult seizure 
genesis has been well  characterized in the cortical subdivi- 
sion of the inferior coll iculus [9,11-13],  this brain area 
should prove to be excel lent model  system to explore 
various strategies of gene therapy. 
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